Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Restructuring Costs (2024 - 2025)

Lyra Therapeutics (LYRA) has disclosed Restructuring Costs for 2 consecutive years, with -$11.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Restructuring Costs fell 521.65% to -$11.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.9 million, a N/A change, with the full-year FY2024 number at $10.9 million, changed N/A from a year prior.
  • Restructuring Costs was -$11.8 million for Q3 2025 at Lyra Therapeutics, down from $12.2 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $12.2 million in Q2 2025 to a low of -$11.8 million in Q3 2025.